Post on 05-Jan-2016
description
Flow of Patients Through Trial
Nissen SE, et al. JAMA 2008;299:1547-60
Baseline Characteristics of the Study Population (n=839)a
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Body Weight, Waist Circumference, Metabolic Outcomes, and Blood Pressure in Patients Completing the Trial (n=676)a
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Effects of Rimonabant on Body Weight, Waist Circumference, and Levels of HDL-C, Triglycerides, Fasting Insulin, and Glycated Hemoglobin (HbA1c)
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Baseline, Follow-up, and Change from Baseline in Intravascular Ultrasound End Points in Patients Completing the Trial (n = 676)
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Primary Efficacy Parameter (Percent Atheroma Volume) in Subgroups
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Major Cardiovascular Adverse Events, Treatment-Emergent Adverse Events, and Reasons for Study Drug Discontinuation (Randomized Population, n=839)
Nis
sen
SE
, et
al.
JAM
A 2
008;
299
:15
47-6
0
Cumulative Incidence of Drug Discontinuation
Nissen SE, et al. JAMA 2008;299:1547-60